Rosuvastatin calcium synthesis method - Patent - …

Aim: D-dimer reportedly plays a leading role in diagnosing pulmonary embolism. Additionally, homocysteine is an established risk factor for atherosclerosis, vascular disease, and thrombosis. Herein, the authors aimed to evaluate the diagnostic significance of D-dimer and homocysteine levels, together with multi-detector computed tomography (CT) in suspected pulmonary embolism. Methods: The authors examined patients suffering from conditions and complaints that are typical of pulmonary artery thromboembolism (PATE), such as chest pain, haemoptysis, dyspnoea, tachycardia, arterial hypotension, and signs of vein thrombosis in the inferior limbs. In these patients, PATE was found in different localizations with varying rates of severity. D-dimer levels were measured in patients with suspected PATE using enzyme-linked immunosorbent assays. Homocysteine levels were determined by an enzymatic method. All patients were examined to evaluate the presence of pulmonary embolism by multi-detector CT angiopulmonography. Results: Changes in homocysteine levels can be considered a separate independent factor for PATE diagnostics. The correlation between multi-detector CT angiopulmonography, elevated D-dimer levels, and concomitant hyperhomocysteinemia can be used not only for diagnostics but also for the assessment of the effectiveness of PATE treatment. Conclusion: Multi-detector CT angiopulmonography, D-dimer levels and related hyperhomocysteinemia can serve as significant laboratory markers in the diagnosis and treatment efficacy of PATE.

Rosuvastatin Calcium Tablets (rosuvastatin calcium): …

HOW SUPPLIED. Atorvastatin/Atorvastatin Calcium/Lipitor Oral Tab: 10mg, 20mg, 40mg, 80mg

Rosuvastatin Calcium | HMG-CoA Reductase inhibitor | …

N2 - 4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and C log P values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.

PROCESS FOR THE SYNTHESIS OF ROSUVASTATIN CALCIUM …

AB - 4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3 + 2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and C log P values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.

synthesis of rosuvastatin calcium:
HOW SUPPLIED. Crestor/Rosuvastatin/Rosuvastatin Calcium Oral Tab: 5mg, 10mg, 20mg, 40mg

Preparation method of rosuvastatin calcium and ..

Aim: D-dimer reportedly plays a leading role in diagnosing pulmonary embolism. Additionally, homocysteine is an established risk factor for atherosclerosis, vascular disease, and thrombosis. Herein, the authors aimed to evaluate the diagnostic significance of D-dimer and homocysteine levels, together with multi-detector computed tomography (CT) in suspected pulmonary embolism. Methods: The authors examined patients suffering from conditions and complaints that are typical of pulmonary artery thromboembolism (PATE), such as chest pain, haemoptysis, dyspnoea, tachycardia, arterial hypotension, and signs of vein thrombosis in the inferior limbs. In these patients, PATE was found in different localizations with varying rates of severity. D-dimer levels were measured in patients with suspected PATE using enzyme-linked immunosorbent assays. Homocysteine levels were determined by an enzymatic method. All patients were examined to evaluate the presence of pulmonary embolism by multi-detector CT angiopulmonography. Results: Changes in homocysteine levels can be considered a separate independent factor for PATE diagnostics. The correlation between multi-detector CT angiopulmonography, elevated D-dimer levels, and concomitant hyperhomocysteinemia can be used not only for diagnostics but also for the assessment of the effectiveness of PATE treatment. Conclusion: Multi-detector CT angiopulmonography, D-dimer levels and related hyperhomocysteinemia can serve as significant laboratory markers in the diagnosis and treatment efficacy of PATE.

Vitamin B-Complex | Michigan Medicine

Aim: The aim of the present article was the detection of threshold heteroplasmy level of mitochondrial DNA mutations, above which a patient is at increased risk of atherosclerotic lesions. Besides, this parameter was detected for mutations, in which after reaching threshold heteroplasmy level, a protective antiatherogenic effect started to appear. Methods: The participants of the study were 700 women and men from the Moscow region. Fragments of DNA, amplified by polymerase chain reaction, were analyzed with pyrosequencing technology. Then on the basis of pyrograms’ peaks in the samples, the heteroplasmy level of the investigated mitochondrial genome mutations was detected. Results: The threshold heteroplasmy level of 11 investigated mutations (m.5178C>A, m.15059G>A, m.652delG, m.13513G>A, m.14846G>A, m.652insG, m.12315G>A, m.3336T>C, m.1555A>G, m.14459G>A, m.3256C>T) in individuals with atherosclerotic plaques or thickening of the intima-medial layer of carotid arteries was detected. Conclusion: Using the method developed in our laboratory, the authors managed to determine threshold heteroplasmy levels of 11 mitochondrial genome mutations associated with atherosclerosis. The authors suggest that threshold heteroplasmy levels of these mutations is a new criterion for evaluation of predisposition to the occurrence and development of atherosclerotic lesions in human arteries.

Dyslipidemia - Endocrine and Metabolic Disorders - …

This study presents the case of a female patient with severe heterozygous familial hypercholesterolemia. Despite the combined maximum dose oral treatment with rosuvastatin and ezetimibe, we found markedly elevated lipid parameters. Therefore, we indicated monthly selective low density lipoprotein (LDL) apheresis treatment using the Direct Adsorption of Lipoproteins system. After more than 2 years the lipid levels of the patients were still above the therapeutic goals. Finally, we completed the treatment by the inhibitor evolocumab biweekly. Further LDL cholesterol (LDL-C) reduction was achieved resulting in lipid parameters on goals. However, administration of evolocumab without LDL apheresis could not reduce the LDL-C below 2.5 mmol/L. We concluded that both LDL apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor treatments were effective and well tolerated. None of them alone would be enough to achieve lipid goals in this patient. However, the combination of these potent treatments may normalize the lipid levels and prevent cardiovascular complications.